文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向肿瘤浸润巨噬细胞可减少肿瘤起始细胞,减轻免疫抑制,并提高化疗反应。

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

机构信息

Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.

出版信息

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.


DOI:10.1158/0008-5472.CAN-12-2731
PMID:23221383
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3563931/
Abstract

Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in aggressive tumors. Consequently, the type and quality of immune responses present in the neoplastic stroma are highly predictive of patient outcome in several cancer types. In addition to host immune responses, intrinsic tumor cell activities that mimic stem cell properties have been linked to chemoresistance, metastatic dissemination, and the induction of immune suppression. Cancer stem cells are far from a static cell population; rather, their presence seems to be controlled by highly dynamic processes that are dependent on cues from the tumor stroma. However, the impact immune responses have on tumor stem cell differentiation or expansion is not well understood. In this study, we show that targeting tumor-infiltrating macrophages (TAM) and inflammatory monocytes by inhibiting either the myeloid cell receptors colony-stimulating factor-1 receptor (CSF1R) or chemokine (C-C motif) receptor 2 (CCR2) decreases the number of tumor-initiating cells (TIC) in pancreatic tumors. Targeting CCR2 or CSF1R improves chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses. Tumor-educated macrophages also directly enhanced the tumor-initiating capacity of pancreatic tumor cells by activating the transcription factor STAT3, thereby facilitating macrophage-mediated suppression of CD8(+) T lymphocytes. Together, our findings show how targeting TAMs can effectively overcome therapeutic resistance mediated by TICs.

摘要

浸润肿瘤的免疫细胞可以促进侵袭性肿瘤的化疗耐药和转移扩散。因此,肿瘤基质中存在的免疫反应的类型和质量高度预测了几种癌症类型患者的预后。除了宿主免疫反应外,与化疗耐药、转移扩散和免疫抑制诱导相关的内在肿瘤细胞活动也类似于干细胞特性。肿瘤干细胞远非静态的细胞群体;相反,它们的存在似乎受到高度动态过程的控制,这些过程依赖于肿瘤基质的信号。然而,免疫反应对肿瘤干细胞分化或扩增的影响还不太清楚。在这项研究中,我们表明通过抑制髓样细胞受体集落刺激因子-1 受体(CSF1R)或趋化因子(C-C 基序)受体 2(CCR2)来靶向浸润肿瘤的巨噬细胞(TAM)和炎性单核细胞,可以减少胰腺肿瘤中的肿瘤起始细胞(TIC)数量。靶向 CCR2 或 CSF1R 可提高化疗疗效、抑制转移并增强抗肿瘤 T 细胞反应。肿瘤诱导的巨噬细胞还通过激活转录因子 STAT3 直接增强胰腺肿瘤细胞的肿瘤起始能力,从而促进巨噬细胞介导的 CD8+T 淋巴细胞抑制。总之,我们的研究结果表明,如何靶向 TAMs 可以有效地克服由 TIC 介导的治疗耐药性。

相似文献

[1]
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Cancer Res. 2012-12-5

[2]
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Cancer Res. 2014-9-15

[3]
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.

Cancer Res. 2018-1-4

[4]
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.

Gut. 2015-10-9

[5]
Targeting both tumour-associated CXCR2 neutrophils and CCR2 macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.

Gut. 2017-12-1

[6]
ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.

Cancer Res. 2021-12-1

[7]
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.

Cancer Immunol Res. 2017-11-2

[8]
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.

J Exp Clin Cancer Res. 2019-8-22

[9]
Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R.

Biomaterials. 2025-1

[10]
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.

Cancer Lett. 2017-1-28

引用本文的文献

[1]
COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion.

Nat Commun. 2025-8-12

[2]
The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy.

Front Immunol. 2025-7-24

[3]
Recent Advances in Nanotechnology-Based Approaches for Ferroptosis Therapy and Imaging Diagnosis in Pancreatic Cancer.

Pharmaceutics. 2025-7-20

[4]
Targeting tumor-associated CCR2 macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation.

Sci Adv. 2025-7-25

[5]
Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention.

J Clin Invest. 2025-7-15

[6]
Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis.

Front Immunol. 2025-5-16

[7]
Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.

Front Immunol. 2025-5-15

[8]
Modulating immune cells within pancreatic ductal adenocarcinoma via nanomedicine.

Essays Biochem. 2025-5-26

[9]
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.

J Exp Clin Cancer Res. 2025-5-16

[10]
The clinical significance and potential therapeutic target of tumor-associated macrophage in non-small cell lung cancer.

Front Med (Lausanne). 2025-4-30

本文引用的文献

[1]
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

ACS Med Chem Lett. 2011-10-5

[2]
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Cancer Cell. 2012-6-12

[3]
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Cancer Cell. 2012-6-12

[4]
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

Cancer Cell. 2012-4-17

[5]
Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

Cancer Cell. 2012-3-20

[6]
Coordinated regulation of myeloid cells by tumours.

Nat Rev Immunol. 2012-3-22

[7]
Interactions between cancer stem cells and their niche govern metastatic colonization.

Nature. 2011-12-7

[8]
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Genes Dev. 2011-12-1

[9]
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Cancer Discov. 2011-6-1

[10]
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.

Nature. 2011-10-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索